Treatment of Relapsed Acute Promyelocytic Leukemia with Gemtuzumab Ozogamicin and All-Trans Retinoic Acid

被引：0
作者：
Tageja, N. [1 ]
Valent, J. [2 ]
Zonder, J. [2 ]
机构：
[1] Wayne State Univ, Dept Internal Med, Detroit Med Ctr, Detroit, MI 48201 USA
[2] Wayne State Univ, Div Hematol Oncol, Karmanos Canc Inst, Detroit, MI 48201 USA
来源：
JOURNAL OF CHEMOTHERAPY | 2009年 / 21卷 / 06期
关键词：
ACUTE MYELOID-LEUKEMIA; ARSENIC TRIOXIDE; CELLS; REMISSION; MYLOTARG;
D O I：
10.1179/joc.2009.21.6.705
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：705 / 706
页数：2
相关论文
共 12 条
[1]   Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3 [J].
Amico, D ;
Barbui, AM ;
Erba, E ;
Rambaldi, A ;
Introna, M ;
Golay, J .
BLOOD, 2003, 101 (11) :4589-4597
[2]   Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia [J].
Aribi, Ahmed ;
Kantarjian, Hagop M. ;
Estey, Elihu H. ;
Koller, Charles A. ;
Thomas, Deborah A. ;
Kornblau, Steven M. ;
Faderl, Stefan H. ;
Laddie, Nakia M. ;
Garcia-Manero, Guillermo ;
Cortes, Jorge E. .
CANCER, 2007, 109 (07) :1355-1359
[3]   Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate [J].
Bernstein, ID .
LEUKEMIA, 2000, 14 (03) :474-475
[4]   Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia [J].
Breccia, Massimo ;
Cimino, Giuseppe ;
Diverio, Daniela ;
Gentilini, Fabiana ;
Mandelli, Franco ;
Lo Coco, Francesco .
HAEMATOLOGICA, 2007, 92 (09) :1273-1274
[5]   Acute promyelocytic leukemia: Relieving repression induces remission [J].
Collins, SJ .
BLOOD, 1998, 91 (08) :2631-2633
[6]   Experience with gemtuzumab ozogamycin ("mylotarg"), and all-trans retinoic acid in untreated acute promyelocytic leukemia [J].
Estey, EH ;
Giles, FJ ;
Beran, M ;
O'Brien, S ;
Pierce, SA ;
Faderl, SH ;
Cortes, JE ;
Kantarjian, HM .
BLOOD, 2002, 99 (11) :4222-4224
[7]   Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia [J].
Lo-Coco, F ;
Cimino, G ;
Breccia, M ;
Noguera, NI ;
Diverio, D ;
Finolezzi, E ;
Pogliani, EM ;
Di Bona, E ;
Micalizzi, C ;
Kropp, M ;
Venditti, A ;
Tafuri, A ;
Mandelli, F .
BLOOD, 2004, 104 (07) :1995-1999
[8]  
PAIETTA E, 1994, LEUKEMIA, V8, P968
[9]   Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Sanz, Miguel A. ;
Grimwade, David ;
Tallman, Martin S. ;
Lowenberg, Bob ;
Fenaux, Pierre ;
Estey, Elihu H. ;
Naoe, Tomoki ;
Lengfelder, Eva ;
Buechner, Thomas ;
Doehner, Hartmut ;
Burnett, Alan K. ;
Lo-Coco, Francesco .
BLOOD, 2009, 113 (09) :1875-1891
[10]   All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study [J].
Soignet, S ;
Fleischauer, A ;
Polyak, T ;
Heller, G ;
Warrell, RP .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (Suppl 1) :S25-S29
12